Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma BRISBANE, Calif. and ST. LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic...

Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments – Seasoned oncology leaders Louie Naumovski, M.D., Ph.D., appointed as Chief Medical Officer; Amit Agarwal, M.D., Ph.D. as Senior V.P., Clinical Development and Steve DeMattos as Senior V.P., Clinical...

Arch Oncology Secures $105 Million Series C Financing – Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies – – Series C co-led by new investors Eventide Asset...